[
  {
    "id": "sprint_mind_bp_cognition",
    "domain": "cardiovascular_risk",
    "title": "SPRINT MIND: intensive blood pressure lowering and reduced dementia risk",
    "source": "Williamson et al., JAMA, 2019; follow-up analysis, 2025",
    "url": "https://jamanetwork.com/journals/jama/fullarticle/2730424",
    "summary": "The SPRINT MIND trial randomized over 9,300 adults with hypertension to intensive blood pressure control (target systolic <120 mmHg) versus standard control (<140 mmHg). The intensive treatment group had a 19% lower rate of probable dementia and a 16% reduction in mild cognitive impairment over roughly five years. The study is among the strongest direct evidence that treating hypertension — one of the most prevalent modifiable risk factors for dementia — meaningfully reduces cognitive decline risk, not just cardiovascular events. Subsequent analysis confirmed the effect was sustained and was not explained by differential use of specific drug classes, suggesting the mechanism is the blood pressure reduction itself rather than a drug-specific effect."
  },
  {
    "id": "ldl_cholesterol_cognitive_risk",
    "domain": "cardiovascular_risk",
    "title": "LDL cholesterol, vascular dementia risk, and the effect of statin intervention",
    "source": "Systematic review and meta-analysis, Journal of Neurology, 2025",
    "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12644782/",
    "summary": "Elevated LDL cholesterol in midlife (roughly ages 40-65) is associated with a significantly higher risk of vascular dementia and all-cause dementia in later life, with hazard ratios in the range of 1.2-1.5 per standard deviation increase, independent of APOE genotype. Statin-mediated LDL reduction, when initiated in midlife rather than late life, has been associated with lower dementia incidence in observational and some interventional data, though the effect is smaller than the robust cardiovascular benefit. High HDL cholesterol (above 60 mg/dL) is consistently associated with lower dementia risk, suggesting the overall cholesterol balance — not just LDL in isolation — matters for brain health."
  },
  {
    "id": "sleep_amyloid_glymphatic",
    "domain": "sleep_glymphatic",
    "title": "Sleep, glymphatic clearance, and amyloid-beta accumulation",
    "source": "Xie et al., Science, 2013; clinical review, Nature Reviews Neuroscience, 2025",
    "url": "https://pubmed.ncbi.nlm.nih.gov/24136970/",
    "summary": "The brain's glymphatic system — a waste-clearance network that becomes most active during slow-wave sleep — is responsible for clearing metabolic waste products including amyloid-beta and tau proteins. Sleep deprivation, even over a single night, measurably elevates amyloid-beta in cerebrospinal fluid and plasma in healthy adults, while chronic poor sleep is associated with accelerated amyloid accumulation on PET imaging over years. Targeting 7-8 hours of quality sleep per night, with emphasis on deep slow-wave sleep stages, is now considered a first-line lifestyle intervention for dementia risk reduction by several major prevention guidelines. Behaviorally, consistent sleep schedules, reduced evening light exposure, and treating underlying sleep-disordered breathing (such as obstructive sleep apnea, which significantly worsens amyloid accumulation) are the evidence-based practical targets."
  },
  {
    "id": "exercise_bdnf_nfl_cognition",
    "domain": "exercise_cognitive_reserve",
    "title": "Exercise, BDNF, neurofilament light chain, and cognitive reserve",
    "source": "Narrative review, Physical Activity and Cognitive Health, 2025",
    "url": "https://www.mdpi.com/2308-3417/10/6/143",
    "summary": "Regular aerobic exercise reduces plasma neurofilament light chain (NfL) — a blood biomarker of ongoing neuronal damage — and increases brain-derived neurotrophic factor (BDNF), which supports hippocampal neurogenesis and synaptic plasticity. Randomized trials of structured walking programs (150+ minutes per week of moderate-intensity aerobic exercise) show significant improvements in memory, executive function, and processing speed in older adults, including those with mild cognitive impairment. Resistance training adds complementary benefits through IGF-1 and irisin signaling. Combined aerobic plus resistance programs outperform either modality alone in most comparative trials. The cognitive benefit appears robust across APOE4 carrier status, making exercise the most consistently evidence-supported modifiable brain-health intervention currently known."
  },
  {
    "id": "mind_diet_brain_health",
    "domain": "diet_nutrition",
    "title": "MIND diet adherence and cognitive decline: evidence and mechanisms",
    "source": "Morris et al., Alzheimer's & Dementia, 2015; NEJM RCT 2023",
    "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa2302368",
    "summary": "The MIND diet — a hybrid of the Mediterranean and DASH diets — emphasizes green leafy vegetables (at least 6 servings/week), other vegetables, nuts, berries, beans, whole grains, fish, poultry, olive oil, and moderate wine consumption, while limiting red meat, butter, cheese, pastries, and fried food. Observational data from the Rush Memory and Aging Project found that high MIND diet adherence was associated with cognitive function equivalent to being 7.5 years younger. The mechanism involves reduced neuroinflammation, improved vascular endothelial function, and the neuroprotective effects of polyphenols, omega-3 fatty acids, and B vitamins (particularly folate, B6, and B12, which reduce homocysteine, an established dementia risk biomarker). The NEJM RCT (2023) found the MIND diet improved some cognitive measures versus a control diet over three years, though effect sizes were smaller than in the earlier observational studies."
  },
  {
    "id": "homocysteine_b_vitamins_cognition",
    "domain": "diet_nutrition",
    "title": "Homocysteine, B vitamins, and cognitive decline prevention",
    "source": "Clarke et al., New England Journal of Medicine, 2010; meta-analysis update 2025",
    "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12434245/",
    "summary": "Elevated plasma homocysteine — driven largely by deficiencies in folate, B6, and B12 — is one of the most consistently replicated blood biomarkers for accelerated cognitive decline and dementia risk. Homocysteine above 14 μmol/L is associated with roughly a 2-fold increase in Alzheimer's risk. B vitamin supplementation (folate, B6, B12) reliably lowers homocysteine and, in individuals who are actually deficient, has been shown in randomized trials to meaningfully slow brain atrophy and cognitive decline over two years. The effect is largest in those who begin supplementation with elevated baseline homocysteine and adequate omega-3 status — suggesting B vitamins and omega-3s work synergistically for brain-health benefit. Testing homocysteine as part of a brain-health panel is therefore directly actionable in a way that many biomarkers are not."
  },
  {
    "id": "diabetes_insulin_cognition",
    "domain": "metabolic_health",
    "title": "Diabetes, insulin resistance, and cognitive decline: type 3 diabetes hypothesis",
    "source": "de la Monte & Wands, Journal of Diabetes Science and Technology, 2008; clinical review 2025",
    "url": "https://pubmed.ncbi.nlm.nih.gov/19885299/",
    "summary": "Type 2 diabetes approximately doubles the risk of Alzheimer's disease and triples the risk of vascular dementia. Insulin resistance in the brain — sometimes called 'type 3 diabetes' — impairs neuronal glucose metabolism, promotes tau phosphorylation, and reduces amyloid clearance. Glycemic control (HbA1c below 7% in diagnosed diabetics) is associated with meaningfully slower cognitive decline. Lifestyle-based approaches — specifically dietary quality improvement and 150+ minutes per week of moderate aerobic exercise — reduce insulin resistance and fasting glucose even in the absence of pharmacological intervention. For clients with prediabetes (fasting glucose 100-125 mg/dL), which is far more prevalent than diagnosed diabetes, lifestyle intervention can prevent progression to T2D and by extension lower the cognitive risk trajectory."
  },
  {
    "id": "depression_dementia_bidirectional",
    "domain": "mental_health_social",
    "title": "Depression, social isolation, and bidirectional dementia risk",
    "source": "Diniz et al., World Psychiatry, 2013; network meta-analysis, Lancet Public Health, 2025",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12762639/",
    "summary": "Depression in midlife increases dementia risk by approximately 65%, making it one of the 12 modifiable risk factors identified in the 2024 Lancet Commission update. The relationship is bidirectional: depression causes neuroinflammation, hypothalamic-pituitary-adrenal axis dysregulation, and reduced hippocampal volume, but early-stage neurodegeneration can also manifest as depression. Social isolation independently doubles dementia risk, likely through overlapping mechanisms involving reduced cognitive reserve and heightened cortisol-mediated neurodegeneration. Both depression treatment (particularly CBT and physical activity, which have similar effect sizes to antidepressants for mild-moderate depression) and social engagement interventions (structured group activities, volunteering, community programs) have evidence-supported roles in dementia prevention."
  },
  {
    "id": "smoking_vascular_brain",
    "domain": "lifestyle_factors",
    "title": "Smoking cessation and dementia risk reduction",
    "source": "Zhong et al., Archives of Internal Medicine, 2015; Lancet Commission 2024",
    "url": "https://pubmed.ncbi.nlm.nih.gov/26039519/",
    "summary": "Current smoking increases the risk of Alzheimer's disease by roughly 45% relative to never-smokers, primarily through accelerated cerebrovascular damage, increased systemic inflammation, and oxidative stress. Critically, former smokers who quit have dementia risk that approaches that of never-smokers within 5-10 years — making smoking cessation one of the few interventions where the benefit of change is both very large and well-documented. The 2024 Lancet Commission listed smoking as a principal modifiable dementia risk factor, and interventions that reduce smoking (pharmacotherapy, behavioral support, combination approaches) consequently carry meaningful brain-health benefit beyond their well-established cardiovascular and cancer risk reductions."
  },
  {
    "id": "alcohol_cognition_dose",
    "domain": "lifestyle_factors",
    "title": "Alcohol consumption, dose-response, and cognitive outcomes",
    "source": "Rehm & Shield, Neuropsychology Review, 2019; global burden update 2025",
    "url": "https://pubmed.ncbi.nlm.nih.gov/30684197/",
    "summary": "High alcohol consumption (more than 14 units per week) is a leading cause of alcohol-related dementia and substantially increases the risk of all-cause dementia through mechanisms including direct neurotoxicity, thiamine (vitamin B1) deficiency causing Wernicke-Korsakoff syndrome, and exacerbation of cardiovascular and liver disease. The relationship between low-to-moderate alcohol and cognition is more contested — earlier observational studies suggesting benefit have largely not been replicated in Mendelian randomization studies, which better control for confounding. The safest conclusion from current evidence is that reduction toward zero or low alcohol consumption is brain-health-protective, with the largest benefit seen in those currently consuming above 14 units per week."
  },
  {
    "id": "finger_multidomain_2015",
    "domain": "exercise_cognitive_reserve",
    "title": "FINGER trial: multidomain lifestyle intervention for cognitive protection",
    "source": "Kivipelto et al., The Lancet, 2015; 11-year follow-up 2026",
    "url": "https://www.sciencedirect.com/science/article/pii/S2666245025000091",
    "summary": "The FINGER trial (n=1,260) demonstrated that a two-year combined intervention of diet, aerobic and resistance exercise, cognitive training, social activity, and vascular risk management produced approximately 25% greater improvement on composite cognitive performance compared to general health advice. Eleven-year follow-up confirmed that greater actual lifestyle change achieved during the trial was associated with better long-term cognitive trajectories, providing evidence that the benefits extend well beyond the active trial period. Critically, FINGER's control group — who received general health advice rather than structured support — had roughly 30% higher risk of cognitive decline, underscoring that knowledge alone is insufficient and that structured, coached, multidomain programs outperform advice-only care."
  },
  {
    "id": "apoe4_lifestyle_metaanalysis",
    "domain": "exercise_cognitive_reserve",
    "title": "Lifestyle interventions benefit APOE4 carriers: pooled analysis of FINGER, MAPT, J-MINT",
    "source": "Alzheimer's & Dementia, PMC12726239, 2025",
    "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC12726239/",
    "summary": "A meta-analysis pooling three randomized controlled trials (FINGER, MAPT, and J-MINT; combined n>3,400) found that multidomain lifestyle interventions benefited APOE4 carriers as much as or more than non-carriers, with statistically significant genotype-by-intervention interactions. This is the first robust evidence that carrying the strongest common genetic risk factor for Alzheimer's does not blunt the benefit of lifestyle intervention and may amplify it — a highly clinically significant finding for genetic risk counseling and prevention program design. Effect sizes were largest in J-MINT (0.36), followed by FINGER (0.15) and MAPT (0.12)."
  },
  {
    "id": "lancet_commission_2024_risk_factors",
    "domain": "cardiovascular_risk",
    "title": "Lancet Commission 2024: 14 modifiable dementia risk factors",
    "source": "Livingston et al., The Lancet, 2024",
    "url": "https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01296-0/fulltext",
    "summary": "The 2024 Lancet Commission update identified 14 modifiable risk factors responsible for approximately 45% of worldwide dementia cases: less education, hearing loss, hypertension, obesity, physical inactivity, diabetes, depression, smoking, excessive alcohol, traumatic brain injury, air pollution, social isolation, vision loss, and high LDL cholesterol. Of these, hypertension (attributable fraction 8.3%), physical inactivity (4.0%), and high LDL cholesterol (7.1%, added in the 2024 update) are among the highest-impact targets for intervention. The Commission explicitly frames population-level dementia prevention as achievable through addressing these modifiable factors, and notes that the global dementia burden could theoretically be reduced by nearly half if all 14 factors were eliminated."
  },
  {
    "id": "ptau217_blood_test_prevention",
    "domain": "cardiovascular_risk",
    "title": "p-tau217 blood biomarker for early Alzheimer's detection and prevention monitoring",
    "source": "Hansson et al., JAMA, 2023; clinical utility review 2025",
    "url": "https://jamanetwork.com/journals/jama/fullarticle/2806545",
    "summary": "Plasma phosphorylated tau 217 (p-tau217) is now recognized as one of the most accurate blood-based early markers of Alzheimer's pathology, with diagnostic accuracy approaching 90% in distinguishing Alzheimer's-related cognitive decline from other causes. P-tau217 can be elevated in blood up to 20 years before clinical symptoms appear, providing a window for preventive intervention long before irreversible neurodegeneration. Critically, several lifestyle interventions associated with better outcomes — particularly blood pressure control, exercise, and reduced metabolic risk factors — have been associated with favorable changes in p-tau217 levels, suggesting the marker may serve as an intermediate monitoring tool for lifestyle-based prevention programs. This is the biological rationale behind BetterBrain-style programs that incorporate p-tau217 alongside lifestyle biomarker panels."
  }
]